Trial Protocol ID USOR 21462_GLSI-21-01_FLAMINGO

Trial Description

A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Trastuzumab-based Therapy (FLAMINGO-01)

Contact us regarding Clinical Trials at or call us at 877-664-7724


  • Jeanine L Werner, M.D.

Disease Types


  • Greenwich Life Sciences NCT ID

  • NCT05232916